Drug Discovery

Twitter

Facebook

Copy Link

Key Facts

Key PlayersIsomorphic Labs, Recursion, Insilico

Top News

Takeda inks $1.7 billion Iambic deal to accelerate AI drug discovery for cancer treatments

Japan's Takeda Pharmaceutical has partnered with AI startup Iambic in a deal exceeding $1.7 billion to design small-molecule drugs targeting cancer and gastrointestinal diseases. The collaboration leverages Iambic's NeuralPLexer model to predict protein binding, potentially compressing traditional six-year drug discovery timelines to less than two years through AI predictions and automated laboratories.

Technology3 sources

Takeda inks $1.7 billion Iambic deal to accelerate AI drug discovery for cancer treatments

Technology3 sources

Sam Altman says OpenAI may invest in AI drug discovery firms and take royalties on breakthroughs

OpenAI CEO Sam Altman revealed the company may invest in or subsidize firms using its AI for drug discovery, taking royalties on successful discoveries instead of charging upfront costs. Speaking at Cisco's AI conference, Altman outlined a potential shift from traditional software pricing to outcome-based financial returns, where OpenAI shares both risk and reward in scientific breakthroughs.

Business2 sources

Sam Altman says OpenAI may invest in AI drug discovery firms and take royalties on breakthroughs

Business2 sources

Prev 1 2 3 45Next